A treatment-standard review concludes that most conventional therapies for antibody-mediated kidney transplant rejection lack robust evidence, while newer approaches such as CD38 antibodies and complement inhibition show the most promise in ongoing trials.
Category
Transplant
Source
Nephrology Dialysis Transplantation
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.